Point72 Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Point72 Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,136,940	Closed	-$43M	–	4309
2026 Q1	$43M	Sell	2,136,940 -146,826	-6%	-$2.37M	0.06%	433
2025 Q4	$36.9M	Buy	+2,283,766	New	+$30.2M	0.04%	552
2022 Q4	–	Sell	-57,800	Closed	-$839K	–	1656
2022 Q3	$839K	Buy	+57,800	New	+$808K	﹤0.01%	1087
2019 Q4	–	Sell	-87,000	Closed	-$1.01M	–	1096
2019 Q3	$1.01M	Sell	87,000 -75,900	-47%	-$1.23M	0.01%	686
2019 Q2	$3.61M	Buy	+162,900	New	+$3.82M	0.02%	574

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 Asset Management's KALV Position: Q2 2026 in Review

Point72 Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,136,940 shares — an estimated $43M sold.

Point72 Asset Management first reported a position in KALV in Q2 2019 and held it in 5 quarters. The position peaked at $43M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Point72 Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Point72 Asset Management sold 2,136,940 KalVista Pharmaceuticals shares in Q2 2026, an estimated $43M.
Point72 Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Point72 Asset Management's KalVista Pharmaceuticals position peaked at $43M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.